Searching in the maze: sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival

Laia Oliveras; Núria Montero; Josep M Cruzado

doi:10.1093/ckj/sfad045

Searching in the maze: sodium-glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival

Clin Kidney J. 2023 Mar 13;16(6):909-913. doi: 10.1093/ckj/sfad045. eCollection 2023 Jun.

Authors

Laia Oliveras¹, Núria Montero¹, Josep M Cruzado^{1

2

3}

Affiliations

¹ N ephrology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Catalonia, Spain.
² Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, L'Hospitalet de Llobregat, Catalonia, Spain.
³ Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, L'Hospitalet de Llobregat, Catalonia, Spain.

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) improve cardiovascular and renal outcomes in chronic kidney disease patients with and without diabetes. Kidney transplant recipients have been excluded from landmark trials using SGLT2is and literature on safety and efficacy are scarce. Recent studies suggest that the SGLT2i use in kidney transplant recipients with diabetes is safe, paving the way to investigate whether SGLT2is could also reduce cardiovascular events and kidney function deterioration in kidney allograft recipients.

Keywords: diabetes; kidney transplant; sodium–glucose cotransporter-2 inhibitors.

Publication types

Editorial